ADVFN - Advanced Financial Network.
HOME» NYSE » M » MJN Stock Price » MJN Stock News

Morgan Stanley Dw Str Sat Att Share News

 Ms Dw Str Sat Att Stock Price
MJN Stock Price
 Ms Dw Str Sat Att Stock Chart
MJN Stock Chart
 Ms Dw Str Sat Att Stock News
MJN Stock News
 Ms Dw Str Sat Att Company Information
MJN Company Information
 Ms Dw Str Sat Att Stock Trades
MJN Stock Trades

Mead Johnson 4Q Profit Falls 14% On Higher Costs

DOW JONES NEWSWIRES Mead Johnson Nutrition Co.'s (MJN) fourth-quarter earnings fell 14% as the company was hit by higher commodities costs and operating expenses. For the new year, the company projected per-share earnings of $3 to $3.10, below recent estimates of analysts polled by Thomson Reuters for $3.18. The company has been focusing on growth in emerging markets, and unveiled plans for a $325 million manufacturing and technology center in Singapore last month. Sales in Asia and Latin America -- which represent about two-thirds of the company's topline -- were up 17%. In North American and Europe, sales were up 6%. Mead Johnson reported a profit of $85.6 million, or 42 cents a share, down from $99.6 million, or 48 cents a share, a year earlier. Excluding litigation and restructuring-related costs, earnings were down at 52 cents from 57 cents. The company in October expected per-share earnings of 51 cents. Revenue increased 14% to $911.3 million amid higher prices and as volume rose 11%. Analysts polled by Thomson Reuters recently expected $896 million. Gross margin eased to 61.1% from 62.3% amid higher commodities costs. Overhead costs rose 8.6% while advertising and promotion expenses were up 15%. Research and development costs were up 39%. The company was hit with a short-lived recall of a batch of powdered Enfamil baby formula last month after a baby in Missouri died from a rare bacterial infection. Early this month U.S. health regulators said tests of the formula showed no signs of contamination and some major retailers began returning the product to their shelves. Mead was spun off from drug maker Bristol-Myers Squibb Co. (BMY) in 2009, one of the largest such deals of the last two decades. Shares closed Wednesday at $72.60 and were inactive premarket. The stock has recovered about 5.6% since hitting a more than 9-month low when the recall was unveiled. -By Tess Stynes, Dow Jones Newswires; 212-416-2481;

Stock News for Morgan Stanley Dw Str Sat Att (MJN)
02/14/201717:35:00WEISSLAW LLP: Mead Johnson Nutrition Company Acquisition May...
02/14/201711:42:56Amended Statement of Ownership (sc 13g/a)
02/13/201717:31:46Amended Statement of Ownership (sc 13g/a)
02/13/201717:08:16Statement of Ownership (sc 13g)
02/13/201708:15:12Additional Proxy Soliciting Materials (definitive) (defa14a)
02/13/201708:15:11Current Report Filing (8-k)
02/11/201703:02:00Reckitt Agrees to Mead Deal -- WSJ
02/10/201716:40:00Harwood Feffer LLP Announces Investigation of Mead Johnson Nutrition...
02/10/201713:28:00Reckitt CEO Rakesh Kapoor Goes From Low Key to a Big Deal
02/10/201708:45:10Amended Statement of Ownership (sc 13g/a)
02/10/201708:22:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 4th...
02/10/201707:58:02Current Report Filing (8-k)
02/10/201707:56:07Additional Proxy Soliciting Materials (definitive) (defa14a)
02/10/201706:25:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 3rd...
02/10/201704:21:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- 2nd...
02/10/201703:11:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion -- Update
02/10/201702:50:00Reckitt Benckiser to Buy Mead Johnson for $16.6 Billion
02/10/201702:31:00Mead Johnson Nutrition Agrees to Be Acquired by Reckitt Benckiser
02/06/201711:44:00Statement of Changes in Beneficial Ownership (4)
02/02/201703:02:00U.K.'s Reckitt in Talks for Baby-Food Maker Mead Johnson -- WSJ

Morgan Stanley Dw Str Sat Att and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations